PDB-code
Browse PDE entries (page 17 of 31)
First 13 14 15 PreviousLast21 20 19 Next| # | Species | PDE Type | PDB | Chain | Alternate Model | Ligand | Details | File |
|---|---|---|---|---|---|---|---|---|
 | Human | PDE4B | 1ror | A | ADENOSINEMONOPHOSPHATE |  | ||
| Human | PDE4B | 1ror | B | ADENOSINEMONOPHOSPHATE | | ||
| Human | PDE4B | 1tb5 | A | A | ADENOSINEMONOPHOSPHATE | | |
| Human | PDE4B | 1tb5 | A | B | ADENOSINEMONOPHOSPHATE | | |
| Human | PDE4B | 1tb5 | B | A | ADENOSINEMONOPHOSPHATE | | |
| Human | PDE4B | 1tb5 | B | B | ADENOSINEMONOPHOSPHATE | | |
| Human | PDE4B | 1xlx | A | CILOMILAST | | ||
| Human | PDE4B | 1xlx | B | CILOMILAST | | ||
| Human | PDE4B | 1xlz | A | (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONEO-(AMINOCARBONYL)OXIME | | ||
| Human | PDE4B | 1xlz | B | (1E)-1-[3-(CYCLOPENTYLOXY)-4-METHOXYPHENYL]ETHANONEO-(AMINOCARBONYL)OXIME | | ||
| Human | PDE4B | 1xm4 | A | 3-(CYCLOPENTYLOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-METHOXYBENZAMIDE | | ||
| Human | PDE4B | 1xm4 | B | 3-(CYCLOPENTYLOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-METHOXYBENZAMIDE | | ||
| Human | PDE4B | 1xm6 | A | (5R)-5-(4-methoxy-3-propoxyphenyl)-5-methyl-1,3-oxazolidin-2-one | | ||
| Human | PDE4B | 1xm6 | B | (5R)-5-(4-methoxy-3-propoxyphenyl)-5-methyl-1,3-oxazolidin-2-one | | ||
| Human | PDE4B | 1xmu | A | 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | | ||
| Human | PDE4B | 1xmu | B | 3-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLOROPYRIDIN-4-YL)-4-(DIFLUOROMETHOXY)BENZAMIDE | | ||
| Human | PDE4B | 1xmy | A | ROLIPRAM | | ||
| Human | PDE4B | 1xmy | B | ROLIPRAM | | ||
| Human | PDE4B | 1xn0 | A | A | ROLIPRAM | | |
| Human | PDE4B | 1xn0 | A | B | ROLIPRAM | | |
| Human | PDE4B | 1xn0 | B | A | ROLIPRAM | | |
| Human | PDE4B | 1xn0 | B | B | ROLIPRAM | | |
| Human | PDE4B | 1xos | A | 5-{2-ETHOXY-5-[(4-METHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-1-METHYL-3-PROPYL-1H,6H,7H-PYRAZOLO[4,3-D]PYRIMIDIN-7-ONE | | ||
| Human | PDE4B | 1xot | A | 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE | | ||
| Human | PDE4B | 1xot | B | 2-{2-ETHOXY-5-[(4-ETHYLPIPERAZIN-1-YL)SULFONYL]PHENYL}-5-METHYL-7-PROPYLIMIDAZO[5,1-F][1,2,4]TRIAZIN-4(1H)-ONE | | ||
| Human | PDE4B | 1y2h | A | 1-(2-CHLOROPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | ||
| Human | PDE4B | 1y2h | B | 1-(2-CHLOROPHENYL)-3,5-DIMETHYL-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | ||
| Human | PDE4B | 1y2j | A | 3,5-DIMETHYL-1-(3-NITROPHENYL)-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | ||
| Human | PDE4B | 1y2j | B | 3,5-DIMETHYL-1-(3-NITROPHENYL)-1H-PYRAZOLE-4-CARBOXYLICACIDETHYLESTER | | ||
| Human | PDE4B | 2qyl | A | 4-[8-(3-nitrophenyl)-1,7-naphthyridin-6-yl]benzoicacid | |
This research was performed as part of the "Phosphodiesterase inhibitors for neglected parasitic diseases" (PDE4NPD) programme, which is supported by the European Union 7th Framework Program (FP7/2007-2013) under grant agreement n° 602666.
